Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study

By D. Grady, N. Wenger, D. Herrington, Steven S. Khan, C. Furberg, D. Hunninghake, E. Vittinghoff, S. Hulley. Annals of Internal Medicine, 2000

715 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. (2002, result): “Venous thromboembolism is an expected complication of postmenopausal hormones, and the pattern over time in WHI is consistent with the findings from HERS and several observational studies.(30,31)”
Spontaneous preterm delivery in primiparous women at low risk in Denmark: population based study (2006, background): “cerning the duration of VT risk increase among HT users.(7,8,16,20) In WHI, the increased risk of VT with CEE was”
Glycemic Effects of Postmenopausal Hormone Therapy: The Heart and Estrogen/progestin Replacement Study: A Randomized, Double-Blind, Placebo-Controlled Trial (2003, background): “However, this potential benefit must be weighed against early risk for coronary events seen with initiation of hormone therapy (29, 53, 54), the threefold increased risk for venous thromboembolic events (55), and increased risk for breast cancer with long-term use (54, 56).”